Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.

Annals of oncology : official journal of the European Society for Medical Oncology - 1 Dec 2021

Hodgson D, Lai Z, Dearden S, Barrett J C, Harrington E A, Timms K, Lanchbury J, Wu W, Allen A, Senkus E, Domchek S M, Robson M

Abstract excerpt

BACKGROUND: Presence of a germline BRCA1 and/or BRCA2 mutation (gBRCAm) may sensitize tumors to poly(ADP-ribose) polymerase (PARP) inhibition via inactivation of the second allele, resulting in gene-specific loss of heterozygosity (gsLOH) and homologous recombination deficiency (HRD). Here we explore whether tissue sample testing provides an additional route to germline testing to inform treatment selection for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Breast Neoplasms

Share to Germ Cells

Share to Germ-Line Mutation

Share to Homologous Recombination

Share to Mutation

Share to Poly(ADP-ribose) Polymerase Inhibitors

Source

Identifiers

PMID: 34500047
DOI: 10.1016/j.annonc.2021.08.2154

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of mutation status and homologous recombination deficiency in tumors of patients with germline BRCA1 or BRCA2 mutations and metastatic breast cancer: OlympiAD.PMID 34500047Read ↗

Landscape of homologous recombination deficiencies in solid tumours: analyses of two independent genomic datasets.Semantic proximity Read ↗

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureSemantic proximity Read ↗

Genomic instability in non-breast or ovarian malignancies of individuals with germline pathogenic variants in BRCA1/2.Semantic proximity Read ↗

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of HeterozygositySemantic proximity Read ↗

Homologous recombination deficiency (HRD) testing in ovarian cancer clinical practice: a review of the literatureSemantic proximity Read ↗

Prevalence of homologous recombination biomarkers in multiple tumor types: an observational study.Semantic proximity Read ↗

A profile on the FoundationFocus CDxBRCA tests.Semantic proximity Read ↗

TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes.Semantic proximity Read ↗

Real-World Germline BRCA Testing, Poly(ADP-ribose) Polymerase Inhibitor Utilization, and Survival Outcomes in Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast CancerSemantic proximity Read ↗

Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation.Semantic proximity Read ↗

A comprehensive literature review and meta-analysis of the prevalence of pan-cancer BRCA mutations, homologous recombination repair gene mutations, and homologous recombination deficiencies.Semantic proximity Read ↗

Questions and answers on PARP inhibitor use in somatic BRCA-mutated breast cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.